Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study.
Schmid P, Krocker J, Morack G, Heilmann V, Blohmer JU, Michniewicz K, Köhler G, Schaller-Kranz T, Possinger K, Elling D. Schmid P, et al. Among authors: blohmer ju. J Cancer Res Clin Oncol. 2004 Nov;130(11):657-63. doi: 10.1007/s00432-004-0599-y. Epub 2004 Aug 20. J Cancer Res Clin Oncol. 2004. PMID: 15322862 Clinical Trial.
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
Untch M, Eidtmann H, du Bois A, Meerpohl HG, Thomssen Ch, Ebert A, Harbeck N, Jackisch C, Heilman V, Emons G, Wallwiener D, Wiese W, Blohmer JU, Höffken K, Kuhn W, Reichardt P, Muscholl M, Pauschinger M, Langer B, Lück HJ. Untch M, et al. Among authors: blohmer ju. Eur J Cancer. 2004 May;40(7):988-97. doi: 10.1016/j.ejca.2004.01.011. Eur J Cancer. 2004. PMID: 15093573 Clinical Trial.
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD; German Breast Group. von Minckwitz G, et al. Among authors: blohmer ju. Ann Oncol. 2005 Jan;16(1):56-63. doi: 10.1093/annonc/mdi001. Ann Oncol. 2005. PMID: 15598939 Free article. Clinical Trial.
Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes.
Kümmel S, Eggemann H, Lüftner D, Gebauer N, Bühler H, Schaller G, Schmid P, Kreienberg R, Emons G, Kriner M, Elling D, Blohmer JU, Thomas A. Kümmel S, et al. Among authors: blohmer ju. Int J Biol Markers. 2007 Jul-Sep;22(3):186-93. doi: 10.1177/172460080702200304. Int J Biol Markers. 2007. PMID: 17922461 Free article. Clinical Trial.
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, Sommer H, Morack G, Wischnewsky MB, Lichtenegger W, Kuemmel S. Blohmer JU, et al. Ann Oncol. 2010 Jul;21(7):1430-1435. doi: 10.1093/annonc/mdp585. Epub 2010 Jan 20. Ann Oncol. 2010. PMID: 20089562 Free article. Clinical Trial.
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Dan Costa S, Gerber B, Engels K, Nekljudova V, von Minckwitz G, Untch M; investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups. Loibl S, et al. Among authors: blohmer ju. Ann Oncol. 2017 Mar 1;28(3):497-504. doi: 10.1093/annonc/mdw610. Ann Oncol. 2017. PMID: 27831502 Free article. Clinical Trial.
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. Loibl S, et al. Among authors: blohmer ju. Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158. Ann Oncol. 2019. PMID: 31095287 Free article. Clinical Trial.
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Fasching PA, et al. Among authors: blohmer ju. Ann Oncol. 2021 Jan;32(1):49-57. doi: 10.1016/j.annonc.2020.10.471. Epub 2020 Oct 21. Ann Oncol. 2021. PMID: 33098995 Free article.
261 results